CIC-BT 1436

Bicycle Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of synthetic medicines called Bicycles®. These are short peptides constrained by a small molecule scaffold into two loops, combining the high affinity and specificity of antibodies with the favorable pharmacokinetic properties of small molecules. The company's lead programs are Bicycle Toxin Conjugates (BTCs), including BT8009 targeting Nectin-4 and BT5528 targeting EphA2, which are being evaluated in various solid tumor indications. Bicycle is also developing immune-modulatory Bicycles and maintains significant collaborations with major pharmaceutical companies like Novartis and Bayer to expand the application of its platform.